Novo Nordisk Company Profile
What is the competitive landscape for NOVO NORDISK
NOVO NORDISK has five approved drugs.
There are two US patents protecting NOVO NORDISK drugs.
Summary for Novo Nordisk
| US Patents: | 2 |
| Tradenames: | 5 |
| Ingredients: | 4 |
| NDAs: | 5 |
| Patent Litigation for Novo Nordisk: | See patent lawsuits for Novo Nordisk |
Drugs and US Patents for Novo Nordisk
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo Nordisk | GLUCAGEN | glucagon hydrochloride | POWDER;INTRAMUSCULAR, INTRAVENOUS | 020918-001 | Jun 22, 1998 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Novo Nordisk Inc | PRANDIMET | metformin hydrochloride; repaglinide | TABLET;ORAL | 022386-001 | Jun 23, 2008 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Novo Nordisk Inc | PRANDIMET | metformin hydrochloride; repaglinide | TABLET;ORAL | 022386-002 | Jun 23, 2008 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Novo Nordisk Inc | INNOFEM | estradiol | TABLET;ORAL | 040312-003 | Nov 19, 1999 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | AP1 | RX | Yes | Yes | 9,968,659*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | AP1 | RX | Yes | Yes | 8,114,833*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Novo Nordisk Inc | INNOFEM | estradiol | TABLET;ORAL | 040312-001 | Nov 19, 1999 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Novo Nordisk
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | 6,004,297 | ⤷ Start Trial |
| Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | 7,235,627 | ⤷ Start Trial |
| Novo Nordisk Inc | VAGIFEM | estradiol | TABLET;VAGINAL | 020908-002 | Nov 25, 2009 | 7,018,992 | ⤷ Start Trial |
| Novo Nordisk Inc | PRANDIMET | metformin hydrochloride; repaglinide | TABLET;ORAL | 022386-001 | Jun 23, 2008 | RE37035 | ⤷ Start Trial |
| Novo Nordisk Inc | PRANDIMET | metformin hydrochloride; repaglinide | TABLET;ORAL | 022386-002 | Jun 23, 2008 | RE37035 | ⤷ Start Trial |
| Novo Nordisk Inc | VAGIFEM | estradiol | TABLET;VAGINAL | 020908-002 | Nov 25, 2009 | 5,860,946 | ⤷ Start Trial |
| Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | 6,458,924 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for NOVO NORDISK drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 1 mg/500 mg and 2 mg/500 mg | ➤ Subscribe | 2009-04-09 |
| ➤ Subscribe | Injection | 18 mg/3 mL prefilled syringe | ➤ Subscribe | 2016-12-12 |
| ➤ Subscribe | Vaginal Tablets | 10 mcg | ➤ Subscribe | 2013-01-02 |
International Patents for Novo Nordisk Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 102417455 | ⤷ Start Trial |
| Japan | 6940512 | ⤷ Start Trial |
| Poland | 1687019 | ⤷ Start Trial |
| Poland | 3423082 | ⤷ Start Trial |
| Spain | 2727854 | ⤷ Start Trial |
| European Patent Office | 1687019 | ⤷ Start Trial |
| Australia | 2004290862 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Novo Nordisk Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1730131 | C01730131/02 | Switzerland | ⤷ Start Trial | PRODUCT NAME: EMPAGLIFLOZIN UND METFORMINHYDROCHLORID; REGISTRATION NO/DATE: SWISSMEDIC 65570 12.11.2015 |
| 2209800 | 122014000114 | Germany | ⤷ Start Trial | PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND LIRAGLUTIDE; AUTHORISATION NO/DATE: EU/1/14/947 20140918 |
| 2498758 | PA2020003,C2498758 | Lithuania | ⤷ Start Trial | PRODUCT NAME: METFORMINO HIDROCHLORIDAS; SAKSAGLIPTINAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; DAPAGLIFLOZINAS ARBA FARMACINIU POZIURIU PRIIMTINAS JO SOLVATAS; REGISTRATION NO/DATE: EU/1/19/1401 20191111 |
| 1261586 | 1290013-0 | Sweden | ⤷ Start Trial | PRODUCT NAME: SAXAGLIPTIN/METFORMIN; REG. NO/DATE: EU/1/11/731/001 20111124 |
| 2875043 | CR 2024 00043 | Denmark | ⤷ Start Trial | PRODUCT NAME: DASIGLUCAGON ELLER ET FARMACEUTISK SALT ELLER SOLVAT DERAF, SASOM DASIGLUCAGONHYDROCHLORID; REG. NO/DATE: EU/1/24/1829 20240725 |
| 2782584 | 301153 | Netherlands | ⤷ Start Trial | PRODUCT NAME: COMPOSITION CONTAINING BOTH ESTRADIOL (17SS-ESTRADIOL), OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF (INCLUDING IN HEMIHYDRATE FORM), AND PROGESTERONE; NATIONAL REGISTRATION NO/DATE: RVG 125821 20210611; FIRST REGISTRATION: BE BE582231 20210406 |
| 2861072 | C202430012 | Spain | ⤷ Start Trial | PRODUCT NAME: COMPOSICION QUE CONTIENE ESTRADIOL, INCLUIDO EN FORMA DE HEMIHIDRATO, Y PROGESTERONA.; NATIONAL AUTHORISATION NUMBER: 85988-NL/H/4994/001/DC; DATE OF AUTHORISATION: 20210528; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): BE582231; DATE OF FIRST AUTHORISATION IN EEA: 20210406 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
